Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Fri, 13.12.2024
Eckert & Ziegler SE
Berlin, 13 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval in Japan. This will pave the way for broader access to cutting-edge dia [ … ]
Thu, 05.12.2024
Eckert & Ziegler SE
Berlin, 5 December 2024. Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the signing of a global su [ … ]
Tue, 03.12.2024
Eckert & Ziegler SE
Berlin, 3 December 2024. The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment.
Dr. Mann who holds a doctorate in physics, joined Eckert & Ziegler in 1998 and initially started as head [ … ]
Mon, 02.12.2024
Eckert & Ziegler SE
Berlin, 02 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success of the common project with the Nuclear Physics Institute of the Czech Academy of Sciences [ … ]
Wed, 27.11.2024
Eckert & Ziegler SE
Berlin, 27 November 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand®, by the European Commission (EC). This enables the use of the radiopharmaceutical medicinal product Theralugand® in routine clinical applications throughout the Europ [ … ]
Fri, 22.11.2024
Eckert & Ziegler SE
Eckert & Ziegler raises its forecast for the current financial year once again.Forecast for 2024:
Sales of around EUR 290 million (raised)
EBIT before special items of around EUR 60 million (raised)
Berlin, 22 November 2024 Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) is once again raising its annual forecast for the current financial [ … ]
Thu, 14.11.2024
Eckert & Ziegler SE
Berlin, November 14, 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 m [ … ]
Wed, 13.11.2024
Eckert & Ziegler SE
Berlin, 13 November 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a collaboration and licence agreement with the Australian-headquartered Telix Pharmaceuticals Limited (Telix) for the use of EZAG’s cyclotron-based technology to produce Ac-225. The contract entitles Eckert & Ziegler to milestone payments from Telix total [ … ]
Tue, 15.10.2024
Eckert & Ziegler SE
3rd quarter of 2024:
Sales of EUR 70.1 million (previous year: EUR 65.9 million)
EBIT before special items of EUR 15.5 million (previous year: EUR 15.1 million)
Net income of EUR 5.3 million (previous year: EUR 9.4 million)
First 9 months of 2024:
Sales of EUR 215.5 million (previous year: EUR 183.9 million)
EBIT before special items of EUR [ … ]
Tue, 08.10.2024
Eckert & Ziegler SE
Berlin, Germany and Sydney, Australia - 08. October 2024 - Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced a new global clinical supply agreement. Eckert & Ziegler will provide its [ … ]